Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2018
Reporting Period: Event-based report regarding a material definitive agreement entered into on February 13, 2018.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes and Agreements
On February 13, 2018, the Company entered into a material definitive agreement with Premier Shockwave Wound Care, Inc. ("PSWC") and Premier Shockwave, Inc. ("PS"). Key terms include:
- Product: Purchase and sale of the dermaPACE System and related equipment.
- Minimum Commitment: A minimum purchase of 100 units over a 3-year period.
- Distribution Rights: PSWC and PS receive limited but exclusive distribution rights to provide dermaPACE Systems to certain governmental healthcare facilities in exchange for royalties paid to the Company.
- Service Obligations: The Company retains responsibility for servicing and repairs of the equipment.
- Change of Control Provisions: The agreement includes options for PSWC stockholders to cause the Company to purchase all PSWC stock, and for the Company to purchase all PSWC stock, based on defined purchase price provisions in the event of a change of control.
- Related Party Transaction: PS and PSWC are owned by Anthony Michael Stolarski, a member of the Company's board of directors and an existing shareholder.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains forward-looking statements regarding projected growth, future revenue, benefits of the investment agreements, and anticipated improvements in earnings. These statements are subject to risks and uncertainties.
Risks and Contingencies:
- Actual results may differ materially from projected results due to known and unknown risks.
- Investors are cautioned not to place undue reliance on forward-looking statements.
- The Company assumes no obligation to update these statements.
- Specific risk factors are detailed in the Company's Annual Report on Form 10-K.
Confidential Treatment: The Company intends to submit a request to redact certain portions of the agreement from public filing.
Investor Verification Checklist
- Verify the full text of the Agreement for Purchase and Sale, Limited Exclusive Distribution and Royalties, and Servicing and Repairs (to be filed as an exhibit to the 2017 Form 10-K).
- Review the related party transaction details involving Anthony Michael Stolarski.
- Examine the "Risk Factors" section of the most recent Form 10-K for specific risks associated with the Company's operations and this new agreement.
- Confirm the specific royalty payment terms and purchase price provisions for the change of control options, as these were not detailed in the summary text.